OHE collaborated with the Centre for Health Economics of the University of York in hosting workshop for policy makers and their advisers on NHS reforms. Discussion centred on economic evidence needed to drive the reforms and the gaps that now exist. The post reports key concerns and observations.
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post.
Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.
At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review and qualitative research on how the field of science policy research has evolved and advanced in the 50 years since its inception.
OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal Products on the European economy and society.